Conference Coverage

Strength of fibromyalgia as marker for seizures questioned


 

AT AES 2016

– The specificity of fibromyalgia as a marker for psychogenic nonepileptic seizures is less reliable than previously described, results from a large analysis showed.

“Fibromyalgia has been referred to as a reliable clinical indicator for differentiating psychogenic nonepileptic seizures from epilepsy, but there hasn’t been a lot of research looking into this idea,” Emily K. Acton said in an interview at the annual meeting of the American Epilepsy Society. In fact, the most recent study to investigate the association focused on a small patient cohort in a tertiary care epilepsy referral center and found that a diagnosis of fibromyalgia had a predictive value of 75% and a specificity of 99% for the diagnosis of psychogenic nonepileptic seizures (Epilepsy Behav. 2005; 6[2]:264-5).

Emily K. Acton discusses her poster presentation. Doug Brunk/Frontline Medical News

Emily K. Acton

In a study led by William O. Tatum, DO, of the department of neurology at Mayo Clinic, Jacksonville, Fla., Ms. Acton, a medical student at the University of Illinois at Chicago, and her associates conducted a case-control study to determine how frequently fibromyalgia is associated with different paroxysmal neurologic disorders, and to explore the use of fibromyalgia as a predictor for psychogenic nonepileptic seizures (PNES) in a mixed population of general neurology patients. They retrospectively reviewed the medical charts of 1,730 consecutive patients seen by a single epileptologist at a neurology clinic in Northeastern Florida between June 17, 2009, and June 15, 2012. Age and gender case-matched controls were used for a between-group comparison.

Ms. Acton reported that of the 1,730 patients studied, 95 (5.5%) had a medical history of fibromyalgia. A majority of the 95 patients (95%) were female, and the mean age was 53 years. In addition, 43% of fibromyalgia patients had a nonparoxysmal, neurologic primary clinical diagnosis, most commonly chronic pain. She said that no differences were seen between fibromyalgia patients and case-matched controls in terms of age, race, marital status, or reason for referral. However, compared with case-matched controls, fibromyalgia patients were underrepresented in education (P = .02) and employment (P = .009).

Paroxysmal events were present in 57% of fibromyalgia patients and in 54% of case-matched controls. Among fibromyalgia patients with paroxysmal disorders, 11% had epileptic seizures, 74% had PNES, and 15% had physiologic nonepileptic events. Among matched controls, 37% had epileptic seizures, 51% had PNES, and 12% had physiologic nonepileptic events (P = .009).

After comparing the two groups of patients, the researchers determined that a historical diagnosis of fibromyalgia had a 61% sensitivity, 64% specificity, 74% positive predictive value, and 49% negative predictive value for the diagnosis of PNES. “Another interesting finding was that quite a few of our fibromyalgia patients felt they didn’t have fibromyalgia,” Ms. Action said. “Unprompted, during the course of their first visit, about 10% of this cohort mentioned to a physician that they were diagnosed with fibromyalgia, but they didn’t believe it.”

In their abstract, the researchers wrote that the study design “and a larger sample size involving mixed general neurology patients may account for the lesser association seen between fibromyalgia and PNES in this study.” They reported having no financial disclosures.

Recommended Reading

Seizures Hit 5% of SLE Patients
MDedge Rheumatology
Serious CNS Events in Lupus Seen in Only 4% of Cases
MDedge Rheumatology
Evidence-Based Apps: Is it possible to diagnose epileptic seizure digitally?
MDedge Rheumatology
Drugs approved in 2013
MDedge Rheumatology
Changing marijuana laws pose health challenges
MDedge Rheumatology
Juvenile facial linear scleroderma is a neurocutaneous disease
MDedge Rheumatology
FDA issues new pregnancy/lactation drug label standards
MDedge Rheumatology
Medicolegal aspects of sleep apnea
MDedge Rheumatology
Good luck convincing patients that generics equal brand-name drugs
MDedge Rheumatology
FDA accepting comments on draft guidelines on compounding law
MDedge Rheumatology